RD13-02 cell therapy for relapsed CD7+ NK/T lymphoma
Part of Cancer clinical trials.
This trial uses a new type of immune cell (RD13-02) to treat a rare and aggressive lymphoma that hasn't responded to other treatments. It targets cancer cells that carry a specific marker called CD7.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 70 years old.
- You need a type of lymphoma called relapsed or refractory NK/T lymphoma that has come back or not responded to treatment.
- Your lymphoma cells must have the CD7 protein (a marker on the cell surface).
- Your bone marrow must contain at least 5% abnormal cells (blasts).
- Your kidneys, liver, heart, and overall health must be good enough for the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new cellular therapy using immune cells (called CD20/CD19 cells) for patients with a certain type of lymphoma that has not been cured by standard treatments. The cells are designed to find and destroy your lymphoma cells, potentially helping you achieve remission.
This trial tests a new type of immune cell therapy (CAR-NK) that targets a protein called CD7 found on some leukemia and lymphoma cells. It may help people whose cancer has not responded to other treatments or has returned.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a type of immunotherapy that uses specially engineered immune cells to find and attack cancer cells that have a marker called CD7. It is for people with T-cell lymphoma or acute leukemia that has come back or not responded to previous treatments.
This trial is studying whether a new kind of cellular therapy, called anti-CD7 CAR-T, can help people with relapsed or refractory T-cell lymphoma/leukemia by targeting a specific protein (CD7) on their cancer cells. The treatment uses your own immune cells that are reprogrammed to find and destroy the malignant cells.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.